Aerie Pharmaceuticals Inc

NASDAQ:AERI   3:59:57 PM EDT
9.10
-0.82 (-8.27%)
Products, Regulatory, Other Pre-Announcement

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For Ar-15512 Eye Drop For Dry Eye Disease

Published: 09/29/2020 10:47 GMT
Aerie Pharmaceuticals Inc (AERI) - Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for Ar-15512 (trpm8 Agonist) Eye Drop for Dry Eye Disease.
Aerie Pharmaceuticals - Expects to Initiate a Phase 2b Clinical Study in Q4 of 2020 for Ar-15512.
Aerie Pharmaceuticals - Expect to Begin Phase 2b Clinical Study, Which Will Be Powered As Phase 3, Later This Year, With Topline Readout in Q3 2021.